Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 20, 2024 - Issue 1
Submit an article Journal homepage
1,389
Views
0
CrossRef citations to date
0
Altmetric
Licensed Vaccines

Serological investigation on the prevalence of poliovirus in Guangdong province: A cross-sectional study

Linxiang Chena Department of Immunization Planning, Luohu District Center for Disease Control and Prevention, Shenzhen, China;b Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, ChinaView further author information
,
Quan Qiub Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, ChinaView further author information
,
Qi Zhub Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, ChinaView further author information
,
Jialing Lib Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, ChinaView further author information
,
Xin Xieb Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, ChinaView further author information
,
Xiaoping Shaob Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, ChinaView further author information
,
Jian Liangb Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, ChinaView further author information
,
Wei Zhangc Institute of Pathogenic Microbiology, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China;d Institute of Pathogenic Microbiology, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, ChinaView further author information
,
Huanying Zhengc Institute of Pathogenic Microbiology, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China;d Institute of Pathogenic Microbiology, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, ChinaView further author information
,
Baisheng Lic Institute of Pathogenic Microbiology, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China;d Institute of Pathogenic Microbiology, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, ChinaView further author information
,
Lin Xue School of Public Health, Sun Yat-sen University, Guangzhou, ChinaView further author information
,
Hanri Zengc Institute of Pathogenic Microbiology, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China;d Institute of Pathogenic Microbiology, Guangdong Provincial Key Laboratory of Pathogen Detection for Emerging Infectious Disease Response, ChinaView further author information
&
Limei Sunb Institute of Immunization Programme, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2300156 | Received 05 Oct 2023, Accepted 23 Dec 2023, Published online: 08 Jan 2024

References

  • Polio vaccines. WHO position paper, January 2014. Wkly Epidemiol Rec. 2014;89(9):73–7.
  • Rachlin A, Patel JC, Burns CC, Jorba J, Tallis G, O’Leary A, Wassilak SGF, Vertefeuille JF. Progress toward polio eradication — worldwide, January 2020–April 2022. MMWR Morb Mortal Wkly Rep. 2022;71(19):650–5. doi:10.15585/mmwr.mm7119a2.
  • Bahl S, Bhatnagar P, Sutter RW, Roesel S, Zaffran M. Global polio eradication – Way Ahead. Indian J Pediatr. 2018;85(2):124–31. doi:10.1007/s12098-017-2586-8.
  • Oberste MS. Progress of polio eradication and containment requirements after eradication. Transfusion. 2018;58(Suppl 3):3078–83. doi:10.1111/trf.15018.
  • Verma H, Iliyasu Z, Craig KT, Molodecky NA, Urua U, Jibir BW, Gwarzo GD, Gajida AU, McDonald S, Weldon WC, et al. Trends in poliovirus seroprevalence in Kano State, Northern Nigeria. Clin Infect Dis. 2018;67(suppl_1):S103–S109. doi:10.1093/cid/ciy637.
  • Zang J, Feng L, Wang J, Wang X, Li K, Zhai X. Should more attention be paid to polio sequela cases in China? Front Public Health. 2022;10:1076970. doi:10.3389/fpubh.2022.1076970.
  • Yu WZ, Wen N, Zhang Y, Wang H-B, Fan C-X, Zhu S-L, Xu W-B, Liang X-F, Luo H-M, Li L. Poliomyelitis eradication in China: 1953–2012. J Infect Dis. 2014;210(Suppl 1):S268–74. doi:10.1093/infdis/jit332.
  • Garon J, Seib K, Orenstein WA, Ramirez Gonzalez A, Chang Blanc D, Zaffran M, Patel M. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016;15(6):693–708. doi:10.1586/14760584.2016.1140041.
  • Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–65. doi:10.1128/CVI.00131-10.
  • Veronesi L, Colucci ME, Capobianco E, Bracchi MT, Zoni R, Palandri L, Affanni P. Immunity status against poliomyelitis in young migrants: a seroprevalence study. Acta Biomed. 2019;90(9–S):28–34. doi:10.23750/abm.v90i9-S.8700.
  • Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, Suykens L, Oberste MS, Weldon WC, Costa-Clemens SA, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394(10193):148–158. doi:10.1016/S0140-6736(19)31279-6.
  • Bhaumik SK, Kulkarni RR, Weldon WC, Silveira ELV, Ahmed H, Gunisetty S, Chandele A, Antia R, Verma H, Sutter R, et al. Immune priming and long-term persistence of memory B cells after inactivated poliovirus vaccine in macaque models: support for at least 2 doses. Clin Infect Dis. 2018;67(suppl_1):S66–S77. doi:10.1093/cid/ciy634.
  • Tan Q, Zhu Q, Zheng H, Zhang B, Wu C, Guo X, Li H, Liu L, Liu Y, Rutherford S, et al. Epidemiological serosurvey of poliovirus in Guangdong, China: a cross-sectional study. Hum Vaccin Immunother. 2018;14(11):2644–8. doi:10.1080/21645515.2018.1487911.
  • Tang G, Yin W, Cao Y, Tan L, Wu S, Cao Y, Fu X, Yan J, Jiang X. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: a systematic review and meta-analysis. Hum Vaccin Immunother. 2018;14(11):2636–43. doi:10.1080/21645515.2018.1489188.
  • Zhang ZJ, Zhang H, Li R, Zeng Y, Li X, Pan J, Sun H, Wang Z, Guo F, Zhang Y, et al. Analysis of antibodies of poliviruses in persistent populations in Beijing, 2012. Zhonghua Yu Fang Yi Xue Za Zhi. 2014;48(9):762–5.
  • Lupi S, Stefanati A, Baldovin T, Roman A, Baldo V, Gabutti G. Assessment of seroprevalence against poliovirus among Italian adolescents and adults. Hum Vaccin Immunother. 2019;15(3):677–82. doi:10.1080/21645515.2018.1547608.
  • Jia S, Tang R, Li G, Hu Y, Liang Q. The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines. BMC Infect Dis. 2020;20(1):641. doi:10.1186/s12879-020-05348-1.
  • Snider CJ, Zaman K, Estivariz CF, Yunus M, Weldon WC, Wannemuehler KA, Oberste MS, Pallansch MA, Wassilak SG, Bari TIA, et al. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. Lancet. 2019;393(10191):2624–2634. doi:10.1016/S0140-6736(19)30503-3.
  • Hartvigsson O, Barman M, Savolainen O, Ross AB, Sandin A, Jacobsson B, Wold AE, Sandberg A-S, Brunius C. Differences between arterial and venous umbilical cord plasma metabolome and association with parity. Metabolites. 2022;12(2):175. doi:10.3390/metabo12020175.
  • Tokuhara D, Hikita N. Cord blood-based approach to assess candidate vaccine adjuvants designed for neonates and infants. Vaccines (Basel). 2021;9(2):95. doi:10.3390/vaccines9020095.
  • Soysal A, Bilazer C, Gönüllü E, Barın E, Çivilibal M. Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy. Hum Vaccin Immunother. 2021;17(10):3484–6. doi:10.1080/21645515.2021.1947099.
  • Ye H, Huang T, Ying ZF, Li GL, Che YC, Zhao ZM, Wang JF, Yang XL, Shi L, Jiang RJ, et al. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (I+III) in different dosage forms]. Zhonghua Yu Fang Yi Xue Za Zhi. 2018;52(1):43–9. doi:10.3760/cma.j.issn.0253-9624.2018.01.009.
  • Zhang Y, Zhu S, Yan D, Liu G, Bai R, Wang D, Chen L, Zhu H, An H, Kew O, et al. Natural type 3/type 2 intertypic vaccine-related poliovirus recombinants with the first crossover sites within the VP1 capsid coding region. PLoS ONE. 2010;5(12):e15300. doi:10.1371/journal.pone.0015300.
  • Wen N, Fang F, Xu W, Wang H, Zhang Y, Su Q, Liu Y, Wang H, Zhu S, Zhang X, et al. Vaccine-associated paralytic poliomyelitis — 8 PLADs, China, October 2012–March 2014. china CDC Wkly. 2020;2(50):955–61. doi:10.46234/ccdcw2020.260.
  • Chen P, Liu Y, Wang H, Liu G, Lin X, Zhang W, Ji F, Xu Q, Tao Z, Xu A, et al. Environmental surveillance complements case-based surveillance of acute flaccid paralysis in polio endgame strategy 2019–2023. Appl Environ Microbiol. 2020;86(15). doi:10.1128/AEM.00702-20.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.